EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Recruiting N/A Interventional Study
Lung Cancer EGFR Gene Mutation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 80
Sex
Any
Study type
Interventional
Purpose
Screening
Participants needed
1,000 (estimated)
Sponsor
Dana-Farber Cancer Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria (Aims 1, 2, and 3) for Group 1 (50 through 80 years of age): * Non-tobacco using (currently) * Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx. * East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, Malaysian * Southeast …
Contacts

Fernando Pacheco

857-215-2794

fernando_pacheco@dfci.harvard.edu

CONTACT

Kylee Coonradt

617-582-8846

kylee_coonradt@dfci.harvard.edu

CONTACT